Last reviewed · How we verify

NCT04823975

Improving Health Insurance Literacy Among Utah's Hispanic Population

Completed NA Results posted Last updated 9 October 2024
What this trial tests

NA trial testing Health Insurance Education Program (HIEP) in Health Knowledge, Attitudes, Practice in 12 participants. Completed in 1 June 2024.

Timeline
20 April 2023
Primary endpoint
12 April 2024
1 June 2024

Quick facts

Lead sponsorUniversity of Utah
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposehealth services research
Enrollment12
Start date20 April 2023
Primary completion12 April 2024
Estimated completion1 June 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Utah

Who can join

Adults 18 to 64, any sex, with Health Knowledge, Attitudes, Practice. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Enrolled Individuals Primary · Post-Assessment survey (Weeks 19 (+/- 2 weeks))

A count of the individuals who enrolled in the study.

GroupValue95% CI
HIEP Intervention9
Number of Completed Sessions Per Enrolled Individual Primary · Post-Assessment survey (Weeks 19 (+/- 2 weeks))

The average number of completed sessions per individual enrolled in the study.

GroupValue95% CI
HIEP Intervention0.83± 0.39
Changes in the Health Insurance Literacy Measure Based on Age Group Secondary · Baseline (Week 0) and Post Assessment survey (Weeks 19 (+/- 2 weeks))

Differences between Health Insurance Literacy Measure (HILM) reported at the baseline and post-assessment survey. Differences will be examined by age. Lower scores indicate lower health insurance literacy, higher scores are better. Scores could range from 6 to 24. We report on a limited number of item from the Health Insurance Literacy Measure. We will report mean and standard deviation at both time points.

Age 18-25
GroupValue95% CI
HIEP Intervention10.5± 6.36
Age 26-64
GroupValue95% CI
HIEP Intervention4.33± 3.50
Changes in the Health Insurance Literacy Measure Based on Language Spoken Secondary · Baseline (Week 0) and Post Assessment survey (Weeks 19 (+/- 2 weeks))

Differences between Health Insurance Literacy Measure (HILM) reported at the baseline and post-assessment survey. Differences will be examined by language spoken. Lower scores indicate lower health insurance literacy, higher scores are better. Scores could range from 6 to 24. We report on a limited number of item from the Health Insurance Literacy Measure. We will report mean and standard deviation at both time points.

English Speaking Preferred
GroupValue95% CI
HIEP Intervention9.00± 4.06
Spanish Speaking Preferred
GroupValue95% CI
HIEP Intervention3.25± 3.77

Sponsor's own description

This is a test of an existing health insurance education program (HIEP) in the Utah Hispanic community (aged 18-64). The study will evaluate whether the HIEP delivered by Utah Health Policy Project (UHPP) staff improves participants' health insurance and cost-related literacy. Participants will complete a brief baseline survey, be guided through the HIEP by UHPP staff, and complete a brief survey after completing the sessions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Health Insurance Education Program (HIEP)

Trials testing the same drug.

Other recruiting trials for Health Knowledge, Attitudes, Practice

Currently open trials in the same condition.

Other University of Utah trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04823975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing